Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of deucravacitinib in adolescents with moderate to severe plaque psoriasis
2023-506296-97-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Deucravacitinib with Placebo (2 arms). Primary endpoints: PASI 75 at Week 16, sPGA 0/1 with at least 2-point reduction at Week 16 and 2 more. Planned start Oct 2025; status: authorised.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2023-506296-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506296-97-00.